Related Experiment Videos
Lamotrigine-induced rash in children
J Dooley1, P Camfield, K Gordon
1Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Insights
A new antiepileptic drug, lamotrigine, caused a rash in five of 68 children. One child developed severe Stevens-Johnson syndrome, highlighting potential risks of this epilepsy medication.
Area of Science:
- Pediatric Neurology
- Dermatology
- Clinical Pharmacology
Background:
- Lamotrigine is a novel antiepileptic medication used in pediatric epilepsy management.
- Assessing the safety profile of new antiepileptic drugs is crucial for clinical practice.
Observation:
- A cohort of 68 children received treatment with lamotrigine.
- Five children (7.35%) developed a rash during lamotrigine treatment.
- One child experienced Stevens-Johnson syndrome while on lamotrigine monotherapy.
Findings:
- The incidence of rash associated with lamotrigine in children was observed to be 7.35%.
- Severe cutaneous adverse reactions, including Stevens-Johnson syndrome, can occur.
- Rash recurrence was noted upon reexposure to lamotrigine, indicating potential hypersensitivity.
Implications:
- Clinicians should be vigilant for dermatological side effects when prescribing lamotrigine to children.
- Early recognition and management of rash are essential to prevent severe outcomes.
- Further research into the mechanisms and risk factors for lamotrigine-induced rash is warranted.
Abstract:
Of 68 children treated with lamotrigine, a new antiepileptic medication, five developed a rash. One child developed Stevens-Johnson syndrome on lamotrigine monotherapy. Of the five patients with the rash, three were admitted to the hospital (two to the intensive care unit). All recovered completely, but one child had a recurrence of the rash within 30 minutes of reexposure to lamotrigine after 6 months.